Document is current

Article History

Received: 30 May 2025

Revised: 16 January 2026

Accepted: 27 January 2026

First Online: 10 February 2026

Competing interests

: All authors have completed and submitted the ICMJE disclosures form. DHS reports consultancy for BVI, DORC, Alcon, Alimera, Complement Therapeutics, Adverum, Vascversa, Abbvie, Roche, Moria, and Novartis, and has received research funding from Roche, BVI, DORC, Bayer, Gyroscope, Alcon, and Alimera. VC reports consultancy for Roche, Bayer, Novartis, Apellis, Boehringer Ingelheim, and EyePoint Pharmaceuticals Inc, and has received research grants from Bayer, Novartis, and Roche. SS reports grants from Bayer, Roche, Boehringer Ingelheim, and AbbVie; consultancy for AbbVie, Alimera Sciences, Amgen, Apellis, Astellas, Bayer, Biogen, Boehringer Ingelheim, Clearside Biomedical, Eyebiotech, EyePoint Pharmaceuticals, Iveric Bio, Janssen Pharmaceuticals, Novo Nordisk, Optos, Ocular Therapeutix, Kriya Therapeutics, OcuTerra, Ripple Therapeutics, Roche, Stealth Biotherapeutics, and Sanofi; payment or honoraria from Bayer, Roche, Boehringer Ingelheim, and AbbVie; meeting/travel support from Bayer and Roche; participation on an advisory board or DSMB for Novo Nordisk; stock or stock options in EyeBiotech; and receipt of materials or services from Boehringer Ingelheim. VC is a member of the Eye editorial board.

: Ethics approval is not required for this systematic survey. We plan to disseminate our results through national and international clinical and methods conferences. We also plan to publish our findings in a peer-reviewed journal widely accessed by ophthalmologists.